Atossa Genetics Inc
$ 2.07
-5.48%
31 Jul - close price
- Market Cap 20,648,200 USD
- Current Price $ 2.07
- High / Low $ 2.19 / 2.05
- Stock P/E N/A
- Book Value 3.54
- EPS -4.37
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -0.79 %
- 52 Week High 19.35
- 52 Week Low 1.70
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$22.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-25 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-25 | 2024-11-12 | 2024-08-12 | 2024-04-01 | 2024-03-28 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -1.11 | -1.34 | -1.05 | -1.05 | -0.75 | -0.05 | -0.9 | -0.75 | -0.75 | -0.09 | -0.75 | -1.2 |
| Estimated EPS | -1.22 | -1.1433 | -1 | -0.85 | -0.82 | -0.0633 | -0.9 | -0.9 | -1 | -0.06 | -1 | -0.9 |
| Surprise | 0.11 | -0.1967 | -0.05 | -0.2 | 0.07 | 0.0133 | 0 | 0.15 | 0.25 | -0.03 | 0.25 | -0.3 |
| Surprise Percentage | 9.0164% | -17.2046% | -5% | -23.5294% | 8.5366% | 21.0111% | 0% | 16.6667% | 25% | -50% | 25% | -33.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATOS
2026-07-30 04:01:10
Atossa Therapeutics Inc (ATOS) has an institutional shareholding score of 3.00, ranking 191 out of 384 in its industry. The institutional shareholding proportion decreased by 14.88% quarter-over-quarter to 22.09%. James Simons is the largest institutional shareholder, holding 1.27% of outstanding shares, with notable activities from other firms like Heights Capital Management and Renaissance Technologies LLC.
2026-07-29 09:01:10
This article provides a detailed quarterly and annual cash flow statement for Atossa Therapeutics Inc (ATOS), covering operating, investing, and financing activities. It presents financial data stretching back several years, highlighting changes in cash flow components. The report also includes an FAQ section explaining key cash flow terms and Atossa Therapeutics Inc's performance in these areas, such as its operating cash flow of -29.76M in fiscal 2025.
2026-07-29 07:40:03
This article provides a risk assessment for Atossa Therapeutics Inc (ATOS), detailing its volatility, financial risk, and investment risk. ATOS has a risk assessment score of 2.56, ranking 205 out of 385 in the Biotechnology & Medical Research industry, with a beta value of 1.24 indicating higher volatility than the S&P 500. The report includes data on maximum drawdown, volatility, return-to-drawdown ratio, skewness, and liquidity metrics over various periods.
2026-07-28 19:40:47
Atossa Therapeutics announced the publication of a peer-reviewed preclinical study in npj Breast Cancer, detailing novel (Z)-endoxifen-related compounds that show potent anti-cancer activity in ER-positive breast cancer models. These compounds demonstrated anti-estrogenic effects, inhibited tumor-cell growth, and showed activity in models with ESR1 mutations, which are associated with endocrine resistance. The findings suggest the potential for these compounds, particularly in combination with CDK4/6 inhibitors, to address recurrent and metastatic ER-positive breast cancer.
2026-07-28 13:10:29
Atossa Therapeutics Inc. announced the publication of a preclinical study in npj Breast Cancer, evaluating five chemical entities related to (Z)-endoxifen. Conducted in collaboration with Mayo Clinic, the study demonstrated anti-estrogenic effects and compelling activity against difficult-to-treat estrogen receptor-positive breast cancer models. These findings support further in vivo safety and efficacy studies for these compounds as potential second- or third-line treatments for recurrent disease.
2026-07-28 12:11:45
Atossa Therapeutics announced the publication of a peer-reviewed preclinical study in npj Breast Cancer detailing five novel (Z)-endoxifen-related compounds (AT416E, AT416Z, AT402E, AT402Z, and AT300) with potent anti-cancer activity in ERα+ breast cancer models, including those with ESR1 mutations. These compounds demonstrated anti-estrogenic and anti-cancer effects across various assays, and in some models, showed additive to synergistic activity when combined with the CDK4/6 inhibitor abemaciclib. While these findings are preclinical and do not establish human safety or efficacy, they highlight a strong rationale for further in vivo evaluation of selected candidates for difficult-to-treat breast cancers.
